Beads/ Particles Segment to Dominate Europe Embolization Agents Market during 2019–2028

According to a new market research study on “Europe Embolization Agents Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product, Application, and End User,” is expected to reach US$ 1,282.95 million by 2028 from US$ 795.79 million in 2021. The market is estimated to grow at a CAGR of 7.1% from 2021 to 2028. Rise Incidence of hypertension, obesity, smoking, and alcoholism is the major factor driving the growth of the Europe embolization agents market. However, huge cost of embolization agents may hinder the growth of Europe embolization agents market. The report provides trends prevailing in the Europe embolization agents market along with the drivers and restraints pertaining to the market growth.

In Europe, Italy, Spain, and France have reported the highest number of COVID-19 cases. According to the European Centre for Disease Prevention and Control (ECDC), as of June 2021, Europe has registered 736,553 deaths so far due to COVID-19. Countries across Europe are witnessing a resurgence in COVID-19 cases after successfully mitigating outbreaks early in the year. Many countries are declaring more cases each day than the daily case count reported during the first wave of the pandemic. As per the ECDC, lockdowns are being reintroduced in the UK, Spain, Italy, and Ireland. Moreover, many country governments are working towards boosting up their cell therapy, gene therapy, and regenerative medicine capabilities. Additionally, in the UK, the practice of cancer and neurological diseases has changed. Increasing COVID-19 has affected the diagnosis and treatment of diseases, due to the diversification of the medical workforce and decision to focus on treating the critically ill. Many research organizations are focusing more on COVID studies and are working hard to better understand the virus. The European Academy of Neurology (EAN) has launched a survey on neurological symptoms in COVID-19 patients to better understand the neurological manifestations of the disease. Thus, the growing focus on SARS-CoV-2 has limited the Europe embolization agents market growth in the last two years.

The embolization agents market is segmented into product, application, end user, and country. Based on product, the market is segmented into coils, beads/particles, plugs, detachable balloons, glue, sponge, liquid embolics, sclerosants, precipitating agents, others. The beads/particles segment held the largest share of the market in 2020. Based on coils the market is divided into detachable coils and pushable coils. The pushable coils segment held the largest share of the market in 2020. Based on beads/particles the market is divided into spherical and non-spherical. The pushable non-spherical segment held the largest share of the market in 2020. Based on application, the market is segmented into neurology, oncology, cardiology, peripheral vascular diseases, and others. In 2020, the oncology segment is likely to hold the largest share of the market. The embolization agents market by end user, is segmented into hospitals, ambulatory surgical centers, cardiac centers, and others. The hospitals segment held the largest share of the market in 2020. Based on country the market is divided into U.K., Germany, France, Italy, Spain, and rest of Europe. In 2020, Germany is likely to hold the largest share of the market.

Abbott; Boston Scientific Corporation; Cook Medical LLC; DePuy Synthes; KANEKA CORPORATION; Medtronic; Merit Medical Systems Inc; Penumbra, Inc.; Stryker Corporation; and Terumo Corporation are among the leading companies in the Europe embolization agents market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, Penumbra has now added low-profile (LP) coil configurations to facilitate durable and efficient embolization’s in more lesions. The current peripheral embolization system is comprised of three distinct detachable technologies: Ruby® Coil, POD®, and Packing Coil (Penumbra, Inc.), all of which are large-volume coils with a caliber like 0.035-inch coils and can be delivered via the company's high-flow LANTERN® (0.025-inch + inner diameter) microcatheter. LANTERN's tip forms are available in straight, 45° angle, and 90° angle combinations, making it ideal for complex embolization’s. Penumbra introduced the LP system in 2020, which consists of Ruby Coil LP and Packing Coil LP, both of which are delivered via low-profile microcatheters (0.0165–0.021 inch).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com